UGT8 Double Nickase Plasmid (h): sc-405110-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UGT8 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- UGT8 Double Nickase Plasmid (h) and UGT8 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting UGT8. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UGT8 Double Nickase Plasmid (h) | sc-405110-NIC | 20 µg | $410.00 | |||
UGT8 Double Nickase Plasmid (h2) | sc-405110-NIC-2 | 20 µg | $410.00 |
Human UGT8 encodes UDP-galactose:ceramide galactosyltransferase, a Golgi-associated enzyme that catalyzes formation of galactosylceramide from ceramide and UDP-galactose, initiating key steps in glycosphingolipid biosynthesis. This activity supports myelin lipid composition, membrane microdomain organization, and signaling processes linked to oligodendrocyte differentiation and neural homeostasis. UGT8-dependent lipid remodeling interfaces with ceramide metabolism and broader sphingolipid pathways that regulate stress responses and cell fate decisions. Altered UGT8 expression or galactosylceramide balance has been associated with demyelinating and neurodegenerative contexts and has also been examined in cancer-related metabolic reprogramming, making it relevant for pathway-focused mechanistic studies.
UGT8 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the UGT8 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within UGT8. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt UGT8 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of UGT8-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.